摘要评价抗体28?8和SP263在各自的检测平台上检测各类肺部病变组织中PD?L1表达的一致性.方法 收集南京医科大学第一附属医院2012年1月1日到2017年1月31日肺部疾病行手术切除标本374例,分别使用28?8和SP263两种抗体在各自的检测平台(Dako和Ventana)上进行PD?L1检测,对最终可评估的336例样本,进行结果的一致性统计分析.结果(1)对非小细胞肺癌样本分析,SP263抗体组中PD?L1的阳性率为57.5%(177/308),28?8抗体组中PD?L1的阳性率为57.5% (177/308),阳性检出的相关系数为0.97,两者间具有显著一致性(P<0.01).(2)肺部良性疾病及癌旁组织阳性率均为10.7%(3/28),阳性符合率100.0%,两种抗体的染色分布也较为一致.结论 28?8及SP263两种抗体在非小细胞肺癌及其他组织中的表达水平较一致,可相辅相成、互相替代,有助于临床用药指导.

abstractsevaluate the concordance of PD?L1 expression in various tissues using antibodies 28?8 and SP263 on their respective detection platforms. Methods Three hundred seventy four specimens of surgical resection of pulmonary diseases in the First Affiliated Hospital of Nanjing Medical University from January 1, 2012 to January 31, 2017 were collected. Totally 374 cases were tested for PD?L1 expression using the two antibodies, 28?8 and SP263, by respective detection platforms (Dako and Ventana). Finally, 336 cases were used for further evaluation, and the results were statistically analyzed for concordance. Results For non?small cell lung carcinoma (NSCLC), the positive rate of PD?L1 was 57.5% (177/308) using SP263, and 57.5% (177/308) using 28?8 antibody. The correlation coefficient was 0.97 (P<0.01). The positive rate of both benign lung diseases and paracancerous tissues was about 10.7% (3/28), and the positive concordance rate was 100.0%. The distribution of both antibodies was also relatively consistent. Conclusions The expression levels of 28?8 and SP263 antibodies in NSCLC and other tissues are relatively consistent, suggesting both antibodies may be complementary and substitute for each other, which may be useful in guiding clinical management.